Señales en vivo de KRON | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	442 697
Volumen promedio	376 179
Capitalización de mercado	60.10M
EPS	$0 ( 2024-03-20 )
Próxima fecha de ganancias	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Olek Elizabeth A	Sell	7 368	Common Stock
2024-02-16	Olek Elizabeth A	Sell	0	Common Stock
2024-02-16	Olek Elizabeth A	Sell	89 120	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	145 795	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	87 500	Stock Option (Right to Buy)

INSIDER POWER
45.50
Last 97 transactions
Buy: 7 377 688 \| Sell: 1 665 671

Volumen Correlación

Largo: -0.19 (neutral)

Corto: -0.66 (moderate negative)

Signal:(63.835) Neutral

Kronos Bio, Inc. Correlación

10 Correlaciones Más Positivas
VVOS	0.892
PASG	0.886
SRTS	0.876
SGBX	0.876
FREQ	0.863
ATHE	0.858
CNDT	0.852
FOSL	0.846
KOD	0.841
VNET	0.84

10 Correlaciones Más Negativas
TYHT	-0.846
VERX	-0.827
BLCT	-0.81
HSTM	-0.81
XOG	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kronos Bio, Inc. Correlación - Moneda/Commodity

0.60
( weak )

0.63
( weak )

0.00
( neutral )

0.19
( neutral )

Kronos Bio, Inc. Finanzas

Annual	2023
Ingresos:	$6.29M
Beneficio Bruto:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2023
Ingresos:	$6.29M
Beneficio Bruto:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-4.46M (0.00 %)
EPS:	$-2.30

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.79

Financial Reports:

No articles found.

Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.